MURA Valuation
Mural Oncology PLC
$
2.750
- Overview
- Forecast
- Valuation
- Earnings
MURA Relative Valuation
MURA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MURA is overvalued; if below, it's undervalued.
Historical Valuation
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
0.42
P/B
Median3y
-0.50
Median5y
-0.50
-293.78
FCF Yield
Median3y
-278.84
Median5y
-278.84
Competitors Valuation Multiple
The average P/S ratio for MURA's competitors is 3.68, providing a benchmark for relative valuation. Mural Oncology PLC Corp (MURA) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
People Also Watch
ELTX
Elicio Therapeutics Inc
5.660
USD
+9.90%
WFCF
Where Food Comes From Inc
10.383
USD
-0.16%
CCG
Cheche Group Inc
0.815
USD
-0.61%
HPH
Highest Performances Holdings Inc
0
USD
+12.03%
BOWN
Bowen Acquisition Corp
11.890
USD
-1.65%
GWH
ESS Tech Inc
2.010
USD
+11.05%
FNGR
FingerMotion Inc
4.080
USD
-0.73%
LITM
Snow Lake Resources Ltd
3.900
USD
+14.37%
VATE
Innovate Corp
6.320
USD
-7.60%
BTCS
BTCS Inc
2.860
USD
-5.61%
FAQ
Is Mural Oncology PLC (MURA) currently overvalued or undervalued?
Mural Oncology PLC (MURA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.11. The fair price of Mural Oncology PLC (MURA) is between to according to relative valuation methord.
What is Mural Oncology PLC (MURA) fair value?
How does MURA's valuation metrics compare to the industry average?
What is the current P/B ratio for Mural Oncology PLC (MURA) as of May 25 2025?
What is the current FCF Yield for Mural Oncology PLC (MURA) as of May 25 2025?
What is the current Forward P/E ratio for Mural Oncology PLC (MURA) as of May 25 2025?